Back to discover
Drug

Plozasiran sodium

Approved · EMA

Also known as Redemplo, plozasiran (as sodium).

RxNorm2727337
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: Redemplo (EMA)

Regulatory2026-06-19EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Plozasiran sodium
Aliases & brands
Redemploplozasiran (as sodium)
RxNorm CUI
2727337
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2026-06-19
Latest approval
2026-06-19
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2026-06-19Approval
Approval: Redemplo (EMA)
Indication: Redemplo is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) (see section 4.2 for patient selection… Show full indication

Redemplo is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) (see section 4.2 for patient selection criteria).

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Regulatory event sources are credited in the Regulatory Timeline above.